ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1314

Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients

Tsukasa Matsubara1, Satoru Koyano2, Keiko Funahashi2, James E. Middleton2, Takako Miura1, Kosuke Okuda1, Takeshi Nakamura1, Akira Sagawa3, Takeo Sakurai4, Hiroaki Matsuno5, Tomomaro Izumihara6, Eisuke Shono7, Kou Katayama8, Toyomitsu Tsuchida9, Mitsuyoshi Iwahashi10, Tomomi Tsuru11 and Motohiro Oribe12, 1Matsubara Mayflower Hospital, Kato, Japan, 2Research Institute of Joint Diseases, Kobe, Japan, 3Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 4Inoue Hospital, Takasaki, Japan, 5Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 6Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 7Shono Rheumatology Clinic, Fukuoka, Japan, 8Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, 9Tsuchida Clinic, Chiba, Japan, 10Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, 11PS Clinic, Fukuoka, Japan, 12Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: etanercept, infliximab, polymorphism and remission

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA treatment. However, there is no method for prediction of remission or low disease activity. Previously, we established and validated SNP algorithms for prediction of remission or non-remission among IFX or ETN-treated RA patients (Matsubara T, et al., The 75th annual meeting of the American College of Rheumatology (ACR).Chicago, IL, USA (2011)). In this study, in order to predict remission or low disease activity with these biologics, we validated a third population sample by using the first and second population algorithms.

Methods: The first population sample included 187 RA patients, the second, 206 patients, and the third, 145 patients, for a total of 538 patients from eleven hospitals in different regions of Japan. Remission criteria and low disease activity were determined by DAS28(CRP) within 24-30 weeks after the initiation of treatment with the biologics. Case-control analyses between 285,548 SNPs and remission or low disease activity was examined by Fisher’s exact test. For each biologic, IFX or ETN, we selected 10 SNPs associated with remission or low disease activity which were common in the analyses of both the first and second population (p < 0.05). We then scored the relationship between each SNP and responsiveness, the estimated total score of 10 SNPs (estimated scoring in each SNP was as follows: homo allele in the majority in remission: +1 point, hetero allele: 0 points, and homo allele in the majority of non-remission: -1 point), and then examined relationship between remission, non-remission, and the total score.

Results: In the validation of the third population sample, accuracy ((true positive+true negative)/total) for prediction of IFX remission or low disease activity using the two combined algorithms was 88.9%. Also, in the validation of the third population sample, accuracy of prediction of ETN remission or low disease activity using two combined algorithms was 76.7%. Therefore, the accuracy of prediction of remission or low disease activity using the two combined algorithms is exponentially better than that of remission or low disease activity algorithms alone.

Conclusion: These highly accurate algorithms using SNP analysis may be useful in the prediction of remission or low disease activity before treatment with IFX or ETN, and in this way can contribute to future tailor-made treatment with biologic agents.


Disclosure:

T. Matsubara,
None;

S. Koyano,
None;

K. Funahashi,
None;

J. E. Middleton,
None;

T. Miura,
None;

K. Okuda,
None;

T. Nakamura,
None;

A. Sagawa,
None;

T. Sakurai,
None;

H. Matsuno,
None;

T. Izumihara,
None;

E. Shono,
None;

K. Katayama,
None;

T. Tsuchida,
None;

M. Iwahashi,
None;

T. Tsuru,
None;

M. Oribe,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-algorithms-using-genome-wide-snp-analysis-for-prediction-of-remission-or-low-disease-activity-for-infliximab-or-etanercept-treated-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.